Hormones and antioxidant systems: Role of pituitary and pituitary-dependent axes

Journal of Endocrinological Investigation

Volumn 33, Issue 6, 2010, Pages 422-433

  Mancini, A ^a   Festa, R ^b   Di Donna, V ^a   Leone, E ^a   Littarru, G P ^c   Silvestrini, A ^a   Meucci, E ^a   Pontecorvi, A ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b Department of Molecular Pathology ^*  (Italy)

^c UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

Author keywords

Antioxidants; Coenzyme Q10; Oxidative stress; Pituitary

Indexed keywords

ALPHA TOCOPHEROL; ARGIPRESSIN; GROWTH HORMONE; HYPOPHYSIS HORMONE; TESTOSTERONE; THIAMAZOLE; THYROID HORMONE; UBIDECARENONE; ANTIOXIDANT; ESTRADIOL; PROLACTIN; UBIQUINONE;

ANTIOXIDANT ACTIVITY; BODY FLUID; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; HOST RESISTANCE; HUMAN; HYPERTHYROIDISM; HYPOPHYSIS ADRENAL SYSTEM; HYPOPHYSIS GONAD SYSTEM; HYPOPHYSIS THYROID SYSTEM; HYPOTHYROIDISM; IN VITRO STUDY; IN VIVO STUDY; LIPID PEROXIDATION; NONHUMAN; OXIDATIVE STRESS; POSTMENOPAUSE; REVIEW; SERUM; TESTOSTERONE BLOOD LEVEL; THYROID FUNCTION; ANIMAL; FEMALE; GONAD; HYPOPHYSIS; MALE; PHYSIOLOGY; THYROID GLAND;

ANIMALS; ANTIOXIDANTS; ESTRADIOL; FEMALE; GONADS; GROWTH HORMONE; HUMANS; MALE; OXIDATIVE STRESS; PITUITARY GLAND; PITUITARY-ADRENAL SYSTEM; PROLACTIN; TESTOSTERONE; THYROID GLAND; UBIQUINONE;

EID: 77955403908     PISSN: 03914097     EISSN: 17208386     Source Type: Journal    
DOI: 10.1007/BF03346615     Document Type: Review

References (146)

1. Halliwell B, Gutteridge JMC. Free radical in biology and medicine. 2nd ed. Oxford: Clarendon Press, 1979.
2. Littarru GP. Energy and defence. Rome: CESI, 1994.
3. Kang D, Hamasaki N. Mitochondrial oxidative stress and mitochondrial DNA. Clin Chem Lab Med 2003, 41: 1281-8.
4. Lancaster JR. Nitric oxide in cells. Am Sci 1992, 80: 248-59.
5. Turrens JF, Boveris A. Generation of superoxyde anion by the NADH dehydrogenase of bovine mitochondria. Biochem J 1980, 191: 421-7.
6. Cross AR, Jones OTG. Enzymic mechanism of superoxyde production. Biochem Biophys Acta 1991, 1057: 281-98.
7. Wolff SP, Jiang ZY, Hunt JV. Protein glycation and oxidative stress in diabetes mellitus and ageing. Free Radical Biol Med 1991, 10: 339-52.
8. 10. J Am Coll Nutr 2001, 20: 591-8.
9. Kaltschmidt B, Sparna T, Kaltschmidt C. Activation of NF-kappa B by reactive oxygen intermediates in the nervous system. Antioxid Redox Signal 1999, 1: 129-44.
10. 10 in plasma by a single dilution step. Anal Biochem 2002, 305: 49-54.
11. 10: an update. Curr Opin Clin Nutr Metab Care 2005, 8: 641-6.
12. Thomas SR, Witting PK, Stocker R. A role for reduced coenzyme Q in atherosclerosis? Biofactors 1999, 9: 207-24.
13. Stocker R, Bowry VW, Frei B. Ubiquinol-10 protects human low density lipoprotein more efficiently against lipid peroxidation than does alpha-tocopherol. Proc Natl Acad Sci U S A 1991, 88: 1646-50.
14. 10 results in increased levels of ubiquinol-10 within circulating lipoproteins and increased resistance of human low-density lipoprotein to the initiation of lipid peroxidation. Biochim Biophys Acta 1992, 1126: 247-54.
15. Yalcin A, Kilinc E, Sagcan A, Kultursay H. Coenzyme Q10 concentrations in coronary artery disease. Clin Biochem 2004, 37: 706-9.
16. Tomasetti M, Alleva R, Solenghi MD, Littarru GP. Distribution of antioxidants among blood components and lipoproteins: significance of Hpids/CoQ10 ratio as a possible marker of increased risk for atherosclerosis. Biofactors 1999, 9: 231-40.
17. Lewis SE, Boyle PM, McKinney KA, Young IS, Thompson W. Total antioxidant capacity of seminal plasma is different in fertile and infertile men. Fertil Steril 1995, 64: 868-70.
18. Rice-Evans C, Miller NJ. Total antioxidant status in plasma and body fluids. Methods Enzymol 1994, 234: 279-93.
19. Meucci E, Milardi D, Mordente A, et al. Total antioxidant capacity in patients with varicoceles. Fertil Steril 2003, 79 (Suppl 3): 1577-83.
20. Resch U, Helsel G, Tatzber F, Sinzinger H. Antioxidant status in thyroid dysfunction. Clin Chem Lab Med 2002, 40: 1132-4.
21. Asayama K, Kato K. Oxidative muscular injury and its relevance to hyperthyroidism. Free Radic Biol Med 1990, 8: 293-303.
22. Dobrzynska MM, Baumgartner A, Anderson D. Antioxidants modulate thyroid hormone- and noradrenaline-induced DNA damage in human sperm. Mutagenesis 2004, 19: 325-30.
23. Venditti P, Di Meo S. Thyroid hormone-induced oxidative stress. Cell Mol Life Sci 2006, 63: 414-34.
24. Hoch FL. Lipids and thyroid hormones. Progr Lipids Res 1988, 27: 199-270.
25. Ademoglu E, Gokkusu C, Yarman S, Azizlerli H. The effect of methimazole on oxidants and antioxidants system in patients with hyperthyroidism. Pharmacol Res 1998, 38: 93-6.
26. Bianchi G, Solaroli E, Zaccheroni V, at al. Oxidative stress and anti-oxidant metabolites in patients with hyperthyroidism: effect of treatment. Horm Metab Res 1999, 31: 620-4.
27. Mancini A, De Marinis L, Calabrò F, et al. Physiopathological relevance of coenzyme Q10 in thyroid disorders: CoQ10 concentrations in normal and diseased human thyroid tissue. In: Folkers K, Littarru GP, Yamagami T, Eds. Biomedical and Clinical Aspects of Coenzyme Q. Amsterdam: Elsevier. 1991, 441-8.
28. Mancini A, Conte G, De Marinis L, Oradei A, Littarru GP. Thyroid hormone and oxidative metabolism: Coenzyme Q10 in thyroid's disease. CoQ Biol Med 1993, 1: 25-34.
29. Fernández V, Barrientos X, Kipreos K, Valenzuela A, Videla LA. Superoxide radical generation, NADPH oxidase activity and cytochrome P-450 content of rat liver microsomal fractions in an experimental hyperthryoid state: relation to lipid peroxidation. Endocrinology 1985, 117: 496-501.
30. Venditti P, Daniele MC, Masullo P, Di Meo S. Antioxidant-sensitive triiodothyronine effects on characteristics of rat liver mitochondrial population. Cell Physiol Biochem 1999, 9: 38-52.
31. Venditti P, Balestrieri M, Di Meo S, De Leo T. Effect of thyroid state on lipid peroxidation, antioxidant defences and susceptibility to oxidative stress in rat tissues. J Endocrinol 1997, 155: 151-7.
32. Huh K, Kwon TH, Kim JS, Park JM. Role of the hepatic xanthine oxidase in thyroid dysfunction: effect of thyroid hormones in oxidative stress in rat liver. Arch Pharmacol Res 1998, 21: 236-49.
33. Choudhury S, Chainy GBN, Mishro MM. Experimentally induced hypo- and hyper-thyroidism influence on the antioxidant defence system in adult rat testis. Andrologia 2003, 35: 131-40.
34. Asayama K, Dobashi K, Hayashibe H, Megata Y, Kato K. Lipid peroxidation and free radical scavengers in thyroid dysfunction in the rat: a possible mechanism of injury to heart and skeletal muscle in hypothyroidism. Endocrinology 1987, 121: 2112-8.
35. 10 determination. J Endocrinol Invest 1989, 12: 511-6.
36. th "Giornate Italiane della Tiroide", S. Margherita Ligure, 1989, p. 67 (abstract).
37. Mancini A, Corbo GM, Gaballo A, et al. Relationships between plasma CoQ10 levels and thyroid hormones in chronic obstructive pulmonary disease. Biofactors 2005, 25: 201-4.
38. Kodama M, Inoue F, Saito H, Oda T, Sato Y. Formation of free radicals from steroid hormones: possible significance in environmental carcinogenesis. Anticancer Res 1997, 17: 439-44.
39. Hornsby PJ. Cytochrome P-450/pseudosubstrate interactions and the role of antioxidants in the adrenal cortex. Endocr Res 1986, 12: 469-94.
40. Patak P, Willenberg HS, Bornstein SR. Vitamin C is an important cofactor for both adrenal cortex and adrenal medulla. Endocr Res 2004, 30: 871-5.
41. Mitani F, Ogishima T, Mukai K, Suematsu M. Ascorbate stimulates monooxygenase-dependent steroidogenesis in adrenal zona glomerulosa. Biochem Biophys Res Commun 2005, 338: 483-90.
42. Das PC, Das KP, Bagchi K, Dey CD. Evaluation of tissue ascorbic acid status in different hormonal states of female rats. Life Sci 1993, 52: 1493-8.
43. Abidi P, Zhang H, Zaidi SM, et al. Oxidative stress-induced inhibition of adrenal steroidogenesis requires participation of p38 mitogen-activated protein kinase signalling pathway. J Endocrinol 2008, 198: 193-207.
44. Celebi F, Yilmaz I, Aksoy H, Gumus M, Taysi S, Oren D. Dehydroepiandrosterone prevents oxidative injury in obstructive jaundice in rats. J Int Med Res 2004, 32: 400-5.
45. Kim SK, Novak RF. The role of intracellular signaling in insulin-mediated regulation of drug metabolizing enzyme gene and protein expression. Pharmacol Ther 2007, 113: 88-120.
46. Jacob MH, Janner Dda R, Belló-Klein A, Llesuy SF, Ribeiro MF. Dehydroepiandrosterone modulates antioxidant enzymes and Akt signalling in healthy Wistar rat hearts. J Steroid Biochem Mol Biol 2008, 112: 138-44.
47. Yildirim A, Sahin YN, Suleyman H, Yilmaz A, Yildirim S. The role of prednisolone and epinephrine on gastric tissue and erythrocyte antioxidant status in adrenalectomized rats. J Physiol Pharmacol 2007, 58: 105-16.
48. Toleikis PM, Godin DV. Alteration of antioxidant status following sympathectomy: differential effects of modified plasma levels of adrenaline and noradrenaline. Mol Cell Biochem 1995, 152: 39-49.
49. Hidalgo J, Gasull T, Garcia A, et al. Role of glucocorticoids and catecholamines on hepatic thiobarbituric acid reactants in basal and stress conditions in the rat. Horm Metab Res 1991, 23: 104-9.
50. Mehta JL, Li D. Epinephrine upregulates superoxide dismutase in human coronary artery endothelial cells. Free Rad Biol Med 2001, 30: 148-53.
51. Kawamura T, Yoshioka T, Bills T, Fogo A, Ichikawa I. Glucocorticoid activates glomerular antioxidant enzymes and protects glomeruli from oxidant injuries. Kidney Int 1991, 40: 291-301.
52. Asayama K, Hayashibe H, Dobashi K, Uchida N, Kato K. Effect of dexamethasone on antioxidant enzymes in fetal rat lungs and kidneys. Biol Neonate 1992, 62: 136-44.
53. Arahuetes RM, Madrid R, Cadenas S, et al. Effect of early maternal adrenalectomy on antioxidant enzymes, GSH, ascorbate, and uric acid in the rat fetal lung at term. Exp Lung Res 1993, 19: 533-43.
54. Keen JA, McLaren M, Chandler KJ, McGorum BC. Biochemical indices of vascular function, glucose metabolism and oxidative stress in horses with equine Cushing's disease. Equine Vet J 2004, 36: 226-9.
55. Zafir A, Banu N. Modulation of in vivo oxidative status by exogenous corticosterone and restraint stress in rats. Stress 2009, 12: 167-77.
56. Tanaka H, Makino Y, Okamoto K. Thioredoxin in the endocrine response to stress. Vitam Horm 1999, 57: 153-75.
57. Makino Y, Okamoto K, Yoshikawa N, et al. Thioredoxin: a redox-regulating cellular cofactor for glucocorticoid hormone action. Cross talk between endocrine control of stress response and cellular antioxidant defense system. J Clin Invest 1996, 98: 2469-77.
58. Zelinskii BA, Vlasenko MV. Lipid peroxidation in patients with chronic adrenal cortex failure. Probl Endokrinol (Mosk) 1990, 36: 37-40.
59. Vargas CR, Wajner M, Sirtori LR, et al. Evidence that oxidative stress is increased in patients with X-linked adrenoleukodystrophy. Biochim Biophys Acta 2004, 20: 26-32.
60. Baschetti R. Chronic fatigue syndrome: an endocrine disease off limits for endocrinologists? Eur J Clin Invest 2003, 33: 1029-31.
61. Prázný M, Jezkové J, Horová E, et al. Impaired microvascular reactivity and endothelial function in patients with Cushing's syndrome: influence of arterial hypertension. Physiol Res 2008, 57: 13-22.
62. Tishenina RS. Alpha-tocopherol concentration of the blood plasma and erythrocytes in patients with symptomatic obesity due to hypothalamo- hypophyseal-adrenal disease. Probl Endokrinol (Mosk) 1986, 32: 25-30.
63. Whitworth JA, Williamson PM, Mangos G, Kelly JJ. Cardiovascular consequences of Cortisol excess. Vasc Health Risk Manag 2005, 1: 291-9.
64. Whitworth JA, Mangos GJ, Kelly JJ. Cushing, Cortisol, and cardiovascular disease. Hypertension 2000, 36: 912-6.
65. Benghuzzi H, Tucci M, Hughes J, Lyon R, Adams S. Glomerular response to adrenocortical hormone alone or in combination with selenomethionine. Biomed Sci Instrum 2005, 41: 74-9.
66. Bednarek J, Wysocki H, Sowinski J. Peripheral parameters of oxidative stress in patients with infiltrative Graves' ophtalmopathy treated with corticosteroids. Immunol Lett 2004, 93: 227-32.
67. Esch T, Stefano GB, Fricchione GL, Benson H. Stress-related disease - a potential role for nitric oxide. Med Sci Monit 2002, 8: RA103-18.
68. Peake JM, Suzuki K, Coombes JS. The influence of antioxidant supplementation on markers of inflammation and the relationship to oxidative stress after exercise. J Nutr Biochem 2007, 18: 357-71.
69. Tiidus PM, Houston ME. Vitamin E status and response to exercise training. Sports Med 1995, 20: 12-23.
70. Mancini A, Leone E, Silvestrini A, et al. Evaluation of antioxidant Systems in pituitary-adrenal axis diseases. Pituitary 2010, 13: 138-45.
71. Karachentsev AN, Mel'chenko IA. Effect of sex hormones on lipid peroxidation in the rat aorta. Eksp Klin Farmakol 1997, 60: 13-6.
72. Sullivan JC, Sasser JM, Pollock JS. Sexual dimorphism in oxidant status in spontaneously hypertensive rats. Am J Physiol Regul Integr Comp Physiol 2007, 292: R764-8.
73. Tarn NN, Ghatak S, Ho SM. Sex hormone-induced alterations in the activities of antioxidant enzymes and lipid peroxidation status in the prostate of Noble rats. Prostate 2003, 55: 1-8.
74. Ahlbom E, Grandison L, Bonfoco E, Zhivotovsky B, Ceccatelli S. Androgen treatment of neonatal rats decreases susceptibility of cerebellar granule neurons to oxidative stress in vitro. Eur J Neurosci 1999, 11: 1285-91.
75. Chisu V, Manca P, Zedda M, Lepore G, Gadau S, Farina V. Effects of testosterone on differentiation and oxidative stress resistance in C1300 neuroblastoma cells. Neuroendocrinol Lett 2006, 27: 807-12.
76. Alexandersen P, Haarbo J, Byrjalsen I, Lawaetz H, Christiansen C. Natural androgens inhibit male atherosclerosis: a study of castrat- ed, cholesterol fed rabbits. Circ Res 1999, 84: 813-9.
77. Deenadayalu VP, White RE, Stallone JN, Gao X, Garcia AJ. Testosterone relaxes coronary arteries by opening the large-conductance, calcium-activated potassium channel. Am J Physiol Heart Circ Physiol 2001, 281: H1720-7.
78. English KM, Mandour O, Steeds RP, Diver MJ, Jones TH, Channer KS. Men with coronary artery disease have lower levels of testosterone than those with normal coronary angiograms. Eur Heart J 2000, 21: 890-4.
79. Morris PD, Pugh PJ, Hall J, Channer KS, Jones TH. The relationship between smoking, statin therapy and testosterone in men with coronary artery disease. Endocrine Abstract 2002, P248.
80. English KM, Steeds R, Jones TH, Channer KS. Testosterone and ischaemic heart disease: is there a link? QJM 1997, 90: 787-91.
81. Webb CM, Adamson DL, de Zeigler D, Collins P. Effect of acute testosterone on myocardial ischaemia in men with coranary artery disease. Am J Cardiol 1999, 83: 437-9.
82. Rosano GMC, Leonardo F, Pagnotta P, et al. Acute anti-ischaemic effect of testosterone in men with coronary artery disease. Circulation 1999, 99: 1666-70.
83. Webb CM, McNeill JG, Hayward CS, de Zeigler D, Collins P. Effects of testosterone on coronary vasomotor regulation in men with coronary heart disease. Circulation 1999, 100: 1690-6.
84. Jones RD, Pugh PJ, Jones TH, Channer KS. The vasodilatory action of testosterone: a potassium channel opening or a calcium channel antagonistic action. Br J Pharmacol 2003, 138: 733-44.
85. Kupelian V, Page ST, Araujo AB, Travison TG, Bremner WJ, McKinlay JB. Low sex hormone-binding globulin, total testosterone, and symptomatic androgen deficiency are associated with development of the metabolic syndrome in nonobese men. J Clin Endocrinol Metab 2006, 91: 843-50.
86. Von Eckardstein A, Wu FCW. Testosterone and cardiovascular disease. In: Nieschlag E and Behre HM (Eds), Testosterone: Action, Deficiency, Substitution. 3rd Ed. Cambridge: Cambridge University Press. 2004, 297-331.
87. Nieschlag E, Behre HM, Bouchard P, et al. Testosterone replacement therapy: current trends and future directions. Hum Reprod 2004, 10: 409-19.
88. Kedziora-Kornatowska K, Bartosz M, Mussur M, Zaslonka J, Kedziora J, Bartosz G. The total antioxidant capacity of blood plasma during cardiovasculary bypass surgery in patients with coronary heart disease. Cell Mol Biol Lett 2003, 8: 973-7.
89. Erel O. A novel automated method to measure total antioxidant response against potent free radical reactions. Clin Biochem 2004, 37: 112-9.
90. Demirbag R, Yilmaz R, Erel O. The association of total antioxidant capacity with sex hormones. Scand Cardiovasc J 2005, 39: 172-6.
91. Mancini A, Leone E, Festa R, et al. Effects of testosterone on antioxidant systems in male secondary hypogonadism. J Androl 2008, 29: 622-9.
92. Felty Q, Xiong WC, Sun D, et al. Estrogen-induced mitochondrial reactive oxygen species as signal-transducing messengers. Biochemistry 2005, 44: 6900-9.
93. Borras C, Gambini J, Vina J. Mitochondrial oxidant generation is involved in determining why females live longer than males. Front Biosci 2007, 12: 1008-13.
94. Vina J, Borras C, Gomez-Cabrera MC, Orr WC. Part of the series: from dietary antioxidants to regulators in cellular signalling and gene expression. Role of reactive of reactive oxygen species and (phyto)oestrogens in the modulation of adaptive response to stress. Free Rad Res 2006, 40: 111-9.
95. Schmidt AJ, Krieg JC, Vedder H. Differential effects of glucocorticoids and gonadal steroids on glutathione levels in neuronal and glial cell systems. J Neurosci Res 2002, 67: 544-50.
96. Lacort M, Leal AM, Liza M, Martin C, Martinez R, Ruiz-Larrea MB. Protective effect of estrogens and catecholestrogens against peroxidative membrane damage in vitro. Lipids 1995, 30: 141-6.
97. Leal AM, Begona Ruiz-Larrea M, Martinez R, Lacort M. Cytoprotective actions of estrogens against tert-butyl hydroperoxyde-induced toxicity in hepatocytes. Biochem Pharmacol 1998, 56: 1463-9.
98. Arnal JF, Douin-Echinard V, Tremollières F, et al. Understanding the controversy about hormonal replacement therapy: insight from estrogen effects on experimental and clinical atherosclerosis. Arch Mal Coeur Vaiss 2007, 100: 554-62.
99. Buyon JP, Korchak HM, Rutherford LE, Ganguly M, Weissmann G. Female hormones reduce neutrophil responsiveness in vitro. Arthritis Reum 1984, 27: 623-30.
100. Bekesi G, Kakucs R, Varbirò S, et al. In vitro effects of different steroid hormones on superoxide anion production of human neu- trophil granulocytes. Steroids 2000, 65: 889-94.
101. Cemeli E, Schmid TE, Anderson D. Modulation by flavonoids of DNA damage induced by estrogen-like compounds. Environ Mol Mutagen 2004, 44: 420-6.
102. Gómez-Zubeldia MA, Hernandez R, Viguera J, Arbues JJ, Aparicio A, Millán JC. Effect of bilateral ovariectomy and ovarian steroid hormones on the antioxidant systems and plasma malondialdehyde levels in Wistar rats. Endocr Res 2000, 26: 97-107.
103. Al-Gubory KH, Bolifraud P, Garrel C. Regulation of key antioxidant enzymatic systems in the sheep endometrium by ovarian steroids. Endocrinology 2008, 149: 4428-34.
104. Lee YM, Cheng PY, Hong SF, et al. Oxidative stress induces vascular heme oxygenase-1 expression in ovariectomized rats. Free Rad Biol Med 2005, 39: 108-17.
105. Joswig M, Hach-Wunderle V, Ziegler R, Nawroth PP. Postmenopausal hormone replacement therapy and the vascular wall: mechanisms of 17 beta-estradiol's effects on vascular biology. Exp Clin Endocrinol Diabetes 1999, 107: 477-87.
106. Agarwal A, Allamaneni SS. Role of free radicals in female reproductive diseases and assisted reproduction. Biomed Online 2004, 9: 338-47.
107. Agarwal A, Gupta S, Sharma RK. Role of oxidative stress in female reproduction. Reprod Biol Online 2005, 3: 28.
108. Massafra C, De Felice C, Gioia D, Buonocore G.. Variations in erythrocyte antioxidant glutathione peroxidase activity during the menstrual cycle. Clin Endocrinol (Oxf) 1998, 49: 63-7.
109. Zhao L, Brinton RD. Select estrogens within the complex formulation of conjugated equine estrogens (Premarin) are protective against neurodegenerative insults: implications for a composition of estrogen therapy to promote neuronal function and prevent Alzheimer's disease. BMC Neurosci 2006, 7: 24.
110. Schmidt AJ, Krieg JC, Vedder H. Antioxidative and steroid systems in neurological and psychiatric disorders. World J Bil Psychiatry 2005, 6: 26-35.
111. Nilsen J. Estradiol and neurodegenerative oxidative stress. Front Neuroendocrinol 2008, 29: 463-75.
112. Subbiah MT. Estrogen replacement therapy and cardioprotection: mechanisms and controversies. Braz J Med Biol Res 2002, 35: 271-6.
113. Parthasarathy S, Khan-Merchant N, Penumetcha M, Santanam N. Oxidative stress in cardiovascular disease. J Nucl Cardiol 2001, 8: 379-89.
114. Louet JF, LeMay C, Mauvais-Jarvis F. Antidiabetic actions of estrogen: insight from human and genetic mouse models. Curr Atheroscler Rep 2004 , 6: 180-5.
115. Zhu X, Bonet B, Gillenwater H, Knopp RH. Opposing effects of estrogen and progestins on LDL oxidation and vascular wall cytotoxicity: implications for atherogenesis. Proc Soc Exp Biol Med 1999, 222: 214-21.
116. Wiseman H, O'Reilly J. The cardioprotective antioxidant activity of dietary phytooestrogens compared to oestrogen. Biochem Soc Trans 1997, 25: 107S.
117. Matsuda T, Saito H, Inoue T, et al. Growth hormone inhibits apoptosis and up-regulates reactive oxygen intermediates production by human polymorphonuclear neutrophils. JPEN J Parenter Enteral Nut 1998, 22: 368-74.
118. Sanz A, Gredilla R, Pamplona R, et al. Effect of insulin and growth hormone on rat heart and liver oxidative stress in control and caloric restricted animals. Biogerontology 2005, 6: 15-26.
119. Brown-Borg HM, Bode AM, Bartke A. Antioxidative mechanisms and plasma growth hormone levels: potential relationship in the aging process. Endocrine 1999, 11: 41-8.
120. Hauck SJ, Aaron JM, Wright C, Kopchick JJ, Bartke A. Antioxidant enzymes, free-radical damage, and response to paraquat in liver and kidney of long-living growth hormone receptor/binding protein gene-disrupted mice. Horm Metab Res 2002, 34: 481-6.
121. Mohn A, Marzio D, Giannini C, Capanna R, Marcovecchio M, Chiarelli F. Alterations in the oxidant-antioxidant status in prepubertal children with growth hormone deficiency: effect of growth hormone replacement therapy. Clin Endocrinol (Oxf) 2005, 63: 537-42.
122. Scacchi M, Valassi E, Pincelli AI, et al. Increased lipid peroxidation in adult GH-deficient patients: effects of short-term GH administration. J Endocrinol Invest 2006, 29: 899-904.
123. Smith JC, Lang D, McEneny J, et al. Effects of GH on lipid peroxidation and neutrophil superoxide anion-generating capacity in hypopituitary adults with GH deficiency. Clin Endocrinol (Oxf) 2002, 56: 449-55.
124. Mancini A, Calabrò F, Fiumara C, et al. Plasma Coenzyme Q10 determination in acromegaly. Exp Clin Endocrinol (Life Sci Adv) 1992, 11: 55-60.
125. Velardez MO, del Carmen Diaz M, Lasaga M, Franchi AM, Duvilanski BH. Estrogen decreases the sensitivity of anterior pituitary to the inhibitory effect of nitric oxide on prolactin relase. Horm Res 2003, 60: 111-5.
126. Bolzán AD, Brown OA, Goya RG, Blanchi MS. Hormonal modulation of antioxidant enzyme activities in young and old rats. Exp Gerontol 1995, 30: 169-75.
127. Shimokawa I, Chiba T, Yamaza H, Komatsu T. Longevity genes: insight from caloric restriction and genetic longevity models. Mol Cells 2008, 26: 427-35.
128. Polisseni F, Faletti AG, Pereira VM, Reis AM, Camargos AF, Reis FM. Prolactin inhibits oocyte release after gonadotropin stimulation in the rat: putative mechanism involving ovarian production of beta-endorphin and prostaglandin. Fertil Steril 2005, 83 (Suppl 1): 1119-24.
129. Gancarczyk M, Kuklinska M, Sadowska J, Strzezek J, Bilinska B. Aromatization and antioxidant capacity in the testis of seasonally breeding bank voles: effects of LH, PRL and IGF-1. Theriogenology 2006, 65: 1376-91.
130. Shiu RPC, Friesen HG. Mechanism of action of prolactin in the control of mammary gland function. Annu Rev Physiol 1980, 42: 83-96.
131. Robaire B, Hermo L. Efferent ducts, epididymis, and vas deferens: structure, functions, an their regulation. In: Knobil E, Neill J, Eds. The Physiology of Reprodution. New York Raven Press, 1998, 999-1080.
132. Gonzalez C, Corbacho AM, Eiserich JP, et al. 16K-prolactin inhibits activation of endothelial nitric oxide synthase, intracellular calcium mobilization, and endothelium-dependent vasorelaxation. Endocrinology 2004, 145: 5714-22.
133. Giusti M, Fazzuoli L, Cavallero D, Valenti S. Circulating nitric oxide changes throughout the menstrual cycle in healthy women and women affected by pathological hyperprolactinemia on dopamine agonist therapy. Gynecol Endocrinol 2002, 16: 407-12.
134. Mancini A, Festa R, Silvestrini A, et al. Hormonal regulation of total antioxidant capacity in seminal plasma. J Androl 2009, 30: 534-40.
135. Lutz-Bucher B, Gonzalez de Aguilar JL, René F, Sée V, Gordon JW, Loeffler J. Oxidative stress and a murine superoxide dismutase-1 mutation promoting amyotrophic lateral sclerosis after neurosecretion in the hypothalamo-neurohypophyseal axis. Neuroendocrinology 1999, 69: 377-84.
136. Brunetti L. Nitric oxide: a gas as a modulator of neuroendocrine secretions. Clin Ter 1994, 144: 147-53.
137. Xu Q, Ganju L, Fawcett TW, Holbrook NJ. Vasopressin-induced heat shock protein expression in renal tubular cells. Lab Invest 1996, 74: 178-87.
138. Vlaskovska M, Knepel W. Beta-endorphin and adrenocorticotropin release from rat adenohypophysis in vitro: evidence for local modulation by arachidonic acid metabolites of the cyclooxygenase and lipoxygenase pathway. Neuroendocrinology 1984, 39: 334-42
139. Pleiner J, Mittermayer F, Schaller G, Marsik C, MacAllister RJ, Wolzt M. Inflammation-induced vasoconscrictor hyporeactivity is caused by oxidative stress. J Am Coll Cardiol 2003, 42: 1656-62.
140. Barrett LK, Singer M, Clapp LH. Vasopressin: mechanisms of action on the vasculature in health and in septic shock. Crit Care Med 2007, 35: 33-40.
141. Saito T. SIADH and other hyponatremic disorders: diagnosis and therapeutic problems. Nippon Jinzo Gakkai Shi 1996, 38: 429-34.
142. Maesaka JK, Batuman V, Yudd M, Salem M, Sved AF, Venkatesan J. Hyponatremia and hypouricemia: differentiation from SIADH. Clin Nephrol 1990, 33: 174-8.
143. Decaux G, Musch W. Clinical laboratory evaluation of the syndrome of inappropriate secretion of antidiuretic hormone. Clin J Am Soc Nephrol 2008, 3: 1175-84.
144. Decaux G, Prospert F, Cauchie P, Soupart A. Dissociation between uric acid and urea clearances in the syndrome of inappropriate secretion of antidiuretic hormone related to salt excretion. Clin Sci (Lond) 1990, 78: 451-5.
145. Decaux G. Difference in solute excretion during correction of hyponatremic patients with cirrhosis or syndrome of inappropriate secretion of antidiuretic hormone by oral vasopressin V2 receptor antagonist VPA-985. J Lab Clin Med 2001, 138: 18-21.
146. Mickel HS, Oliver CN, Starke-Reed PE. Protein oxidation and myelinolysis occur in brain following rapid correction of hyponatremia. Biochem Biophys Res Commun 1990, 172: 92-7.